Castle Biosciences IncNASDAQ:CSTL
- LAST PRICE30.2550
- TODAY'S CHANGE (%)-0.1850 (-0.6078%)
- Bid / Lots30.2100/ 6
- Ask / Lots30.3000/ 6
- Open / Previous Close30.4400 / 30.4400
- Day Range
- 52 Week Range
- Volume91,270
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CSTL |
|---|---|---|
| 09:32 ET | 9344 | 30.44 |
| 09:33 ET | 200 | 30.525 |
| 09:37 ET | 200 | 30.28 |
| 09:39 ET | 400 | 30.2 |
| 09:42 ET | 1609 | 30.14 |
| 09:44 ET | 3086 | 30.52 |
| 09:46 ET | 100 | 30.5 |
| 09:48 ET | 400 | 30.58 |
| 09:50 ET | 100 | 30.58 |
| 09:51 ET | 1554 | 30.53 |
| 09:53 ET | 100 | 30.37 |
| 09:57 ET | 395 | 30.36 |
| 10:00 ET | 200 | 30.31 |
| 10:02 ET | 100 | 30.31 |
| 10:04 ET | 100 | 30.35 |
| 10:06 ET | 200 | 30.3 |
| 10:11 ET | 800 | 30.335 |
| 10:13 ET | 300 | 30.33 |
| 10:20 ET | 300 | 30.13 |
| 10:22 ET | 846 | 30 |
| 10:24 ET | 999 | 29.86 |
| 10:26 ET | 200 | 29.85 |
| 10:27 ET | 4636 | 30.15 |
| 10:29 ET | 100 | 30.05 |
| 10:31 ET | 1300 | 30 |
| 10:33 ET | 200 | 29.984 |
| 10:36 ET | 100 | 29.96 |
| 10:38 ET | 100 | 29.96 |
| 10:40 ET | 800 | 29.965 |
| 10:44 ET | 200 | 30.03 |
| 10:45 ET | 100 | 30.05 |
| 10:47 ET | 500 | 30.185 |
| 10:51 ET | 1118 | 30.228 |
| 10:54 ET | 300 | 30.37 |
| 10:56 ET | 100 | 30.33 |
| 11:02 ET | 400 | 30.145 |
| 11:03 ET | 1000 | 30.1544 |
| 11:12 ET | 200 | 30.06 |
| 11:16 ET | 224 | 30.07 |
| 11:20 ET | 6501 | 29.96 |
| 11:21 ET | 1251 | 30.17 |
| 11:34 ET | 200 | 30.09 |
| 11:38 ET | 1100 | 30.11 |
| 11:39 ET | 597 | 30.16 |
| 11:56 ET | 2415 | 30.31 |
| 11:59 ET | 698 | 30.31 |
| 12:01 ET | 400 | 30.265 |
| 12:03 ET | 100 | 30.26 |
| 12:06 ET | 250 | 30.2262 |
| 12:12 ET | 200 | 30.2 |
| 12:14 ET | 100 | 30.25 |
| 12:19 ET | 300 | 30.12 |
| 12:26 ET | 100 | 30.095 |
| 12:32 ET | 400 | 30.22 |
| 12:33 ET | 644 | 30.125 |
| 12:35 ET | 1112 | 30.28 |
| 12:37 ET | 200 | 30.18 |
| 12:39 ET | 100 | 30.255 |
| 12:42 ET | 200 | 30.25 |
| 12:44 ET | 100 | 30.31 |
| 12:46 ET | 200 | 30.39 |
| 12:48 ET | 300 | 30.33 |
| 12:51 ET | 926 | 30.31 |
| 12:53 ET | 100 | 30.21 |
| 12:55 ET | 312 | 30.235 |
| 12:57 ET | 1964 | 30.27 |
| 01:00 ET | 29642 | 30.255 |
Nov 20, 2024
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference, from 7:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 19, 2024
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year, from 7:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 8, 2024
Nov 7, 2024
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher(R) Barrett's Esophagus Test, from 7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
DJ Castle Biosciences Is Maintained at Sector Outperform by Scotiabank, from 11:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
11:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Castle Biosciences Inc | 852.5M | 151.3x | --- |
Paragon 28 Inc | 836.4M | -13.6x | --- |
Mesa Laboratories Inc | 632.5M | -2.6x | --- |
OrthoPediatrics Corp | 614.8M | -20.9x | --- |
Figs Inc | 871.6M | 87.6x | --- |
Treace Medical Concepts Inc | 515.8M | -8.6x | --- |
Company Information
Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.
Contact Information
- Headquarters
- 505 S Friendswood Drive, Suite 401FRIENDSWOOD, TX, United States 77546
- Phone
- 281-796-9032
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Daniel Bradbury
- President, Chief Executive Officer, Founder, Director
- Derek Maetzold
- Chief Financial Officer
- Frank Stokes
- Chief Operating Officer
- Kristen Oelschlager
- Chief Commercial Officer
- Tobin Juvenal
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $852.5M |
|---|---|
Revenue (TTM) | $311.9M |
Shares Outstanding | 28.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.92 |
EPS | $0.20 |
Book Value | $14.27 |
P/E Ratio | 151.3x |
Price/Sales (TTM) | 2.7 |
Price/Cash Flow (TTM) | 43.7x |
Operating Margin | -0.33% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
